Brind.

Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.

3 reports, 2 independent Updated Jul 27
Gone quiet
Reports
3
Developments
3
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.

Who's involved

What this event is mainly about
DMDDyn

How it developed

Newest first. Tap a step to see who reported it.
  1. Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.Sub-event
  2. Dyne is developing therapies for DMD and myotonic dystrophy type 1.1 source
  3. Hercules provided debt financing to Dyne Therapeutics.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • stlmag.comHow a St. Louis insurance exec used AI to help his wife's facial paralysis
  • Insider MonkeyRBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July
  • Unknown outlet